A phase2 trial of dose-adjusting Capecitabine plus stopped Oxaliplatin after six cycles in a XELOX regimen with Bevacizumab for untreated metastatic colorectal cancer. (GOSG C-04 trial)
收藏NIAID Data Ecosystem2026-03-07 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2629133
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: dose-adjusting Capecitabine + Oxaliplatin + Bevacizumab
Primary outcome(s): Progression Free Survival
Study Design: Single arm Non-randomized
创建时间：
2013-02-15
